by In particular, at 21 days of differentiation CoPP (0.5 M) was able to increase HO-1 expression by 10.6 fold (P< 0.05) with respect to undifferentiated cells, whereas cells treated with CoPP (0.5 M) and glucose 30 mM showed an increase of HO-1 expression by 15 fold (P< 0.05) with respect to undifferentiated cells (Fig. levels of osteonectin, OPG, and BMP-2. Inhibition of HO activity prevented the increase in osteonectin and potentiated the decrease of osteocalcin and OPG in cells exposed to high glucose levels. Furthermore, targeting HO-1 expression increased pAMPK and endothelial nitric oxide synthase (eNOS) and restored osteoblastic markers. Our findings suggest that targeting HO-1 gene expression attenuates the hyperglycemia-mediated decrease in MSC-derived osteoblast differentiation. Finally, the mechanism underlying the HO-1-specific cell effect on osteoblasts and adipocytes is yet to be explored. Thus, the targeting of HO-1 gene expression presents a portal to increase osteoblast function and differentiation and attenuate osteoporosis by promoting bone formation. Keywords:Osteopenia, Osteoporosis, MSC, Diabetes, HO-1 == Introduction == Human bone marrow-derived mesenchymal stem cells (MSCs) are multipotent cells that have the potential to proliferate and differentiate into a variety of cell types characteristic of bone, skeletal and cardiac muscle, adipose tissue, and neural cells [1-4]. Diabetes affects dynamic bone formation in Punicalagin both humans and animals, leading to osteopenia and osteoporosis [5,6]. Bone mineral density and biochemical markers of bone turnover are adversely affected in individuals with diabetes [7]. Reduction of bone mass, occurring with increased frequency in individuals Punicalagin with Punicalagin diabetes mellitus, has been attributed to poor glycemic control, but the pathogenic mechanisms remain unknown. High concentrations of glucose (hyperglycemia) in diabetics exacerbate this complication [7-9]. Osteoblasts secrete growth factors including platelet-derived growth factor, insulin-like growth factors, and bone morphogenetic proteins (BMPs) [10] that are stored in the bone matrix. Whether these factors are affected by diabetes remains to be seen. The molecular mechanism underlying osteoblastic differentiation has not been fully elucidated. Recently, Abraham et al. [12] have shown the essential role of HO-1 in restoration of mice bone marrow-derived stem cells [11] and prevention of type 2 diabetes. HO-1 increases stem cell differentiation to various lineages [13-15]. Heme oxygenase-1 (HO-1) plays Rabbit polyclonal to Sin1 a major role during bone marrow stem cell differentiation [16-18]. Heme oxygenase, which exists in two forms, HO-1 (inducible) and HO-2 (constitutive), catalyzes the rate-limiting step in heme degradation, resulting in the formation of carbon monoxide (CO), iron, and biliverdin; the latter is subsequently reduced to bilirubin by biliverdin reductase. Both CO and nitric oxide (NO) protect against tumor necrosis factor-induced apoptosis in osteoblasts [19]. In addition, during fracture repair, activation of hypoxia-inducible factor (HIF)-1 and its target genes, vascular endothelial growth factor (VEGF) and HO-1, regulate osteoclastogenesis and bone reabsorption [20], suggesting a role of HO-1 in bone metabolism. HO-1 expression decreases adipogenesis in obese animals [11,19-21], suggesting that HO-1 may have a differential effect other than that described for vascular smooth muscle cells and endothelial cells [19,22]. HO-1 expression is increased as an adaptive response to several injurious stimuli including Punicalagin heme, hyperoxia, hypoxia, endotoxin, and heavy metals [23]. Induction of HO-1 is implicated in numerous clinically relevant disease states including transplant rejection, hypertension, atherosclerosis, lung damage, and endotoxic surprise [16,19,23]. The suggested role from the HO-1/HO-2 program in osteoblast cell proliferation is due to the observation that HO-1 is normally a powerful regulator of cell development and angiogenesis. The result of HO-1-produced CO signaling to advertise angiogenesis in individual microvessel endothelial cells is normally more developed [24]. Previously, we’ve showed that Punicalagin overexpression from the HO-1 gene in endothelial cells triggered a significant upsurge in angiogenesis [25], somatic cell development [26], and cell proliferation [27]. Adjustments in HO-1-produced CO modulate vascular calcification [28]. Osteocalcin, an osteoblast-specific proteins, is normally of significant significance in metabolic disease and it is secreted in the flow from osteoblastic cells [29,30]. Osteocalcin regulates blood sugar fat burning capacity and body fat mass in modified mice [31] genetically. Osteocalcin-knockout mice screen decreased-cell proliferation,.
